Currently Viewing:
ACO & Emerging Healthcare Delivery Coalition® Spring 2017
Dr Mark Friedberg: How Practices Shifting to Value-Based Care Models Can Alleviate Burnout
November 16, 2017
Dr Frank James on the Role of Stigma in Addiction Treatment
November 15, 2017
Dr Darius Lakdawalla Discusses the Meaning and Measure of "Value" in Healthcare
September 13, 2017
Currently Reading
Dr Darius Lakdawalla on the Willingness to Pay for a Cure
August 02, 2017
Michael Griffin Describes Daughters of Charity's Long History of Leadership
July 21, 2017
Dr Sachin Jain Discusses CareMore's Community Partnerships, Internal Programs
July 18, 2017
Lee Barrett Outlines Best Practices for Healthcare Cybersecurity
July 15, 2017
Michael Griffin on Aligning Payers With Population Health and Social Determinants
July 12, 2017
Dr Clifford Goodman on Possible Drug Pricing Solutions Adapted From Abroad
July 11, 2017
Dr Sachin Jain on CareMore's Mission to Manage Chronic Disease From the Dentist's Chair
July 08, 2017
Michael Griffin Discusses Daughters of Charity's Ongoing Technology Initiatives
July 03, 2017
Lee Barrett: Increased Data Exchange in Value-Based Models Poses Cybersecurity Risks
June 29, 2017
Michael Griffin: Katrina's Lasting Effects on New Orleans and Its Healthcare System
June 22, 2017
Dr Clifford Goodman Discusses Evidence-Based Drug Pricing as an Alternative to Legislative Controls
June 21, 2017
Dr Sachin Jain Focuses on Bipartisan Healthcare Efforts, Not Policy Changes
June 15, 2017
Lee Barrett on the Balance Between Strong Cybersecurity and Patient Access to Data
June 13, 2017
Dr Clifford Goodman on What to Look Forward to at the Fall 2017 ACO Coalition Meeting
June 09, 2017
Dr Sachin Jain: Discussion on Population Health Reveals Causes for Optimism
June 01, 2017
Dr Clifford Goodman: Why Focus on Value Will Persist Regardless of Changing Legislation
May 29, 2017

Dr Darius Lakdawalla on the Willingness to Pay for a Cure

Medical bankruptcy is indefensible and even if patients are willing to bankrupt themselves to purchase a cure, doesn't mean that is how pricing and reimbursement of treatments should be handled, said Darius Lakdawalla, PhD, Quintiles Chair in Pharmaceutical Development and Regulatory Innovation at the School of Pharmacy at the University of Southern California


Medical bankruptcy is indefensible and even if patients are willing to bankrupt themselves to purchase a cure, doesn't mean that is how pricing and reimbursement of treatments should be handled, said Darius Lakdawalla, PhD, Quintiles Chair in Pharmaceutical Development and Regulatory Innovation at the School of Pharmacy at the University of Southern California

Transcript (slightly modified)

What are the arguments for and against the notion that because people are willing to pay for a cure, that justifies the high price?

I think medical bankruptcy is indefensible from both an ethical and economic standpoint. The real issue here is that, it may well be the case, a patient who’s sick is willing, in that particular moment, to bankrupt herself for purchase of the care. But, that’s not really indicative of how we should handle pricing and reimbursement.

If they are so interested in bankrupting themselves, or so willing to bankrupt themselves, it also means that the insurance coverage is extremely valuable to them. So, we need to make sure that there is access to health insurance that is meaningful and in turn provides access to care. That’s the ultimate solution to medical bankruptcy because people do want to pay for healthcare when they’re sick, but it’s much more efficient, ethical, and practical, for us all to pay for healthcare in the form of health insurance premiums when we’re healthy.

 
Copyright AJMC 2006-2017 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up
×

Sign In

Not a member? Sign up now!